Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if so...

Full description

Bibliographic Details
Main Authors: Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Camillo Porta, Daniel Olive, Ida De Luca, Chiara Brando, Mimma Rizzo, Carlo Messina, Mattia Rediti, Antonio Russo, Viviana Bazan, Juan Lucio Iovanna
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
btn3a1
btn2a1
butyrophilins
circulating immune checkpoints
immunotherapy response
pd-1
pd-l1
predictive biomarker
renal cell carcinoma
soluble immune-checkpoints
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1832348

Internet

http://dx.doi.org/10.1080/2162402X.2020.1832348

Similar Items